Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Express News | Travere Therapeutics Inc : Guggenheim Raises to Buy From Neutral
Guggenheim Upgrades Travere Therapeutic(TVTX.US) to Buy Rating, Announces Target Price $25
There's No Escaping Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Muted Revenues Despite A 29% Share Price Rise
Travere (TVTX.US) receives full approval from the FDA for its "first-in-class" therapy, significantly slowing down the decline of kidney function.
On September 7, Travere Therapeutics (TVTX.US) announced that the U.S. FDA has fully approved the "first-in-class" therapy Filspari (sparsentan).
